Comparative effects of oral conjugated equine estrogens and micronized 17β-estradiol on breast proliferation: A retrospective analysis

Menopause

Volumn 15, Issue 5, 2008, Pages 890-898

  Wood, Charles E ^a   Clarkson, Thomas B ^a   Chen, Haiying ^a   Veenstra, Timothy D ^b   Xu, Xia ^a   Scott, Latanya ^a   Cline, J Mark ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

Bioidentical hormones; Breast cancer risk; Cell proliferation; Conjugated equine estrogens; Estradiol; Hormone therapy

Indexed keywords

16ALPHA HYDROXYESTRONE; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN DERIVATIVE; KI 67 ANTIGEN; PLACEBO; PROGESTERONE RECEPTOR; CONTRACEPTIVE AGENT; ESTROGEN RECEPTOR; MEDROXYPROGESTERONE ACETATE;

ANIMAL EXPERIMENT; ANTIBODY LABELING; ARTICLE; BREAST; BREAST EPITHELIUM; CONTROLLED STUDY; DRUG EFFECT; ENDOMETRIUM; ESTROGEN URINE LEVEL; FEMALE; MACACA; NONHUMAN; OUTCOME ASSESSMENT; POSTMENOPAUSE; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; ANIMAL; BREAST TUMOR; CELL PROLIFERATION; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; ESTROGEN THERAPY; HUMAN; METHODOLOGY; PATHOLOGY; RISK FACTOR;

ANIMALS; BREAST; BREAST NEOPLASMS; CELL PROLIFERATION; CONTRACEPTIVE AGENTS, FEMALE; ENDOMETRIUM; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; POSTMENOPAUSE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 58249089220     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e318168f0ad     Document Type: Article

References (71)

1. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712.
2. Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006;295:1647-1657.
3. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003;289:3243-3253.
4. Bergkvist L, Adami HO, Persson I, Hoover R, Schairer C. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 1989;321:293-297.
5. Steinberg KK, Thacker SB, Smith SJ, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991;265:1985-1990.
6. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589-1593.
7. Henrich JB, Kornguth PJ, Viscoli CM, Horwitz RI. Postmenopausal estrogen use and invasive versus in situ breast cancer risk. J Clin Epidemiol 1998;51:1277-1283.
8. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Estrogen-progestin replacement and risk of breast cancer. JAMA 2000;284:691-694.
9. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000;92:328-332.
10. Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-427.
11. Reeves GK, Beral V, Green J, Gathani T, Bull D, Million Women Study Collaborators. Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol 2006;7:910-918.
12. Colditz GA. Estrogen, estrogen plus progestin therapy, and risk of breast cancer. Clin Cancer Res 2005;11:909S-917S.
13. Collins JA, Blake JM, Crosignani PG. Breast cancer risk with postmenopausal hormonal treatment. Hum Reprod Update 2005;11:545-560.
14. Moorman PG, Kuwabara H, Millikan RC, Newman B. Menopausal hormones and breast cancer in a biracial population. Am J Public Health 2000;90:966-971.
15. Warren MP. A comparative review of the risks and benefits of hormone replacement therapy regimens. Am J Obstet Gynecol 2004;190:1141-1167.
16. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006;354:270-282.
17. Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med 2001;344:276-285.
18. Yue W, Santen RJ, Wang JP, et al. Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis. J Steroid Biochem Mol Biol 2003;86:477-486.
19. Cavalieri EL, Rogan EG. A unifying mechanism in the initiation of cancer and other diseases by catechol quinones. Ann N Y Acad Sci 2004;1028:247-257.
20. Cavalieri E, Chakravarti D, Guttenplan J, et al. Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention. Biochim Biophys Acta 2006;1766:63-78.
21. Key T, Appleby P, Barnes I, Reeves G, Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606-616.
22. Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst 2004;96:1856-1865.
23. Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004;96:1751-1761.
24. Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747-2757.
25. Crivellari D, Sun Z, Coates AS, et al. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. J Clin Oncol 2008;26:1972-1979.
26. Robertson JF. Fulvestrant (Faslodex®) how to make a good drug better. Oncologist 2007;12:774-784.
27. Cline JM, Soderqvist G, von Schoultz E, Skoog L, von Schoultz B. Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques. Am J Obstet Gynecol 1996;174:93-100.
28. Cline JM, Soderqvist G, von Schoultz E, Skoog L, von Schoultz B. Effects of conjugated estrogens, medroxyprogesterone acetate, and tamoxifen on the mammary glands of macaques. Breast Cancer Res Treat 1998;48:221-229.
29. Foth D, Cline JM. Effects of mammalian and plant estrogens on mammary glands and uteri of macaques. Am J Clin Nutr 1998;68:1413S-1417S.
30. Cline JM, Register TC, Clarkson TB. Effects of tibolone and hormone replacement therapy on the breast of cynomolgus monkeys. Menopause 2002;9:422-429.
31. Wood CE, Register TC, Anthony MS, Kock ND, Cline JM. Breast and uterine effects of soy isoflavones and conjugated equine estrogens in postmenopausal female monkeys. J Clin Endocrinol Metab 2004;89:3462-3468.
32. Wood CE, Clarkson TB, Appt SE, et al. Effects of soybean glyceollins and estradiol in postmenopausal female monkeys. Nutr Cancer 2006;56:74-81.
33. Wood CE, Register TC, Franke AA, Anthony MS, Cline JM. Dietary soy isoflavones inhibit estrogen effects in the postmenopausal breast. Cancer Res 2006;66:1241-1249.
34. Wood CE, Hester JM, Appt SE, Geisinger KR, Cline JM. Estrogen effects on epithelial proliferation and benign proliferative lesions in the postmenopausal primate mammary gland. Lab Invest 2008; Epub (DOI: 10.1038/labinvest. 2008.64).
35. Wood CE, Register TC, Lees CJ, Chen H, Kimrey S, Cline JM. Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys. Breast Cancer Res Treat 2007;101:125-134.
36. Wellings SR, Jensen HM, Marcum RG. An atlas of subgross pathology of the human breast with special reference to possible pre-cancerous lesions. J Natl Cancer Inst 1975;55:231-273.
37. Veronese SM, Gambacorta M. Detection of Ki67 proliferation rate in breast cancer. Correlation with clinical and pathologic features. Am J Clin Pathol 1991;95:30-34.
38. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki67 in early breast cancer. J Clin Oncol 2005;23:7212-7220.
39. Weidner N, Moore DH, Vartanian R. Correlation of Ki67 antigen expression with mitotic figure index and tumor grade in breast carcinomas using the novel "paraffin"-reactive MIB1 antibody. Hum Pathol 1994;25:337-342.
40. Chang J, Powles TJ, Allred DC, et al. Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients. Clin Cancer Res 2000;6:616-621.
41. Preston-Martin S, Pike MC, Ross RK, Jones PA, Henderson BE. Increased cell division as a cause of human cancer. Cancer Res 1990;50:7415-7421.
42. Petz LN, Ziegler YS, Schultz JR, Nardulli AM. Fos and Jun inhibit estrogen-induced transcription of the human progesterone receptor gene through an activator protein-1 site. Mol Endocrinol 2004;18:521-532.
43. Cline JM, Soderqvist G, von Schoultz B, Skoog L. Regional distribution of proliferating cells and hormone receptors in the mammary gland of surgically postmenopausal macaques. Gynecol Obstet Invest 1997;44:41-46.
44. Cline JM. Assessing the mammary gland of nonhuman primates: effects of endogenous hormones and exogenous hormonal agents and growth factors. Birth Defects Res B Dev Reprod Toxicol 2007;80:126-146.
45. Xu X, Keefer LK, Waterhouse DJ, Saavedra JE, Veenstra TD, Ziegler RG. Measuring seven endogenous ketolic estrogens simultaneously in human urine by high-performance liquid chromatography-mass spectrometry. Anal Chem 2004;76:5829-5836.
46. Wood CE, Register TC, Cline JM. Soy isoflavonoid effects on endogenous estrogen metabolism in postmenopausal female monkeys. Carcinogenesis 2007;28:801-808.
47. Price TM, Blauer KL, Hansen M, Stanczyk F, Lobo R, Bates GW. Single-dose pharmacokinetics of sublingual versus oral administration of micronized 17β-estradiol. Obstet Gynecol 1997;89:340-345.
48. Kabat GC, Chang CJ, Sparano JA, et al. Urinary estrogen metabolites and breast cancer: a case-control study. Cancer Epidemiol Biomarkers Prev 1997;6:505-509.
49. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
50. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004;291:47-53.
51. Boothby LA, Doering PL, Kipersztok S. Bioidentical hormone therapy: a review. Menopause 2004;11:356-367.
52. Whitehead M, Farmer R. The Million Women Study: a critique. Endocrine 2004;24:187-193.
53. Banks E, Reeves G, Beral V, et al. Hormone replacement therapy and false positive recall in the Million Women Study: patterns of use, hormonal constituents and consistency of effect. Breast Cancer Res 2006;8:R8.
54. Mueck AO, Seeger H, Wallwiener D. Comparison of the proliferative effects of estradiol and conjugated equine estrogens on human breast cancer cells and impact of continuous combined progestogen addition. Climacteric 2003;6:221-227.
55. Dimitrakakis C, Zhou J, Wang J, et al. A physiologic role for testosterone in limiting estrogenic stimulation of the breast. Menopause 2003;10:292-298.
56. Zhou J, Ng S, Adesanya-Famuiya O, Anderson K, Bondy CA. Testosterone inhibits estrogen-induced mammary epithelial proliferation and suppresses estrogen receptor expression. FASEB J 2000;14:1725-1730.
57. Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 1999;84:4559-4565.
58. Bhavnani BR, Woolever CA. Interaction of ring B unsaturated estrogens with estrogen receptors of human endometrium and rat uterus. Steroids 1991;56:201-210.
59. Bhavnani BR. Estrogens and menopause: pharmacology of conjugated equine estrogens and their potential role in the prevention of neurodegenerative diseases such as Alzheimer's. J Steroid Biochem Mol Biol 2003;85:473-482.
60. Lugar CW 3rd, Magee D, Adrian MD, Shetler P, Bryant HU, Dodge JA. B-ring unsaturated estrogens: biological evaluation of 17 α-dihydroequilein and novel B-Nor-6-thiaequilenins as tissue selective estrogens. Bioorg Med Chem Lett 2003;13:4281-4284.
61. Hsieh RW, Rajan SS, Sharma SK, Greene GL. Molecular characterization of a B-ring unsaturated estrogen: implications for conjugated equine estrogen components of Premarin. Steroids 2007;73:59-68.
62. Washburn SA, Honore EK, Cline JM, et al. Effects of 17 α-dihydroequilenin sulfate on atherosclerotic male and female rhesus monkeys. Am J Obstet Gynecol 1996;175:341-351.
63. Baracat E, Haidar M, Lopez FJ, Pickar J, Dey M, Negro-Vilar A. Estrogen activity and novel tissue selectivity of δ8,9-dehydroestrone sulfate in postmenopausal women. J Clin Endocrinol Metab 1999;84:2020-2027.
64. Washburn SA, Adams MR, Clarkson TB, Adelman SJ. A conjugated equine estrogen with differential effects on uterine weight and plasma cholesterol in the rat. Am J Obstet Gynecol 1993;169:251-256.
65. Campagnoli C, Ambroggio S, Biglia N, Sismondi P. Conjugated estrogens and breast cancer risk. Gynecol Endocrinol 1999;13:13-19.
66. Song RX, Santen RJ. Membrane initiated estrogen signaling in breast cancer. Biol Reprod 2006;75:9-16.
67. Labrie F, El-Alfy M, Berger L, et al. The combination of a novel selective estrogen receptor modulator with an estrogen protects the mammary gland and uterus in a rodent model: the future of postmenopausal women's health? Endocrinology 2003;144:4700-4706.
68. Komm BS, Kharode YP, Bodine PV, Harris HA, Miller CP, Lyttle CR. Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology 2005;146:3999-4008.
69. Greendale GA, Reboussin BA, Sie A, et al. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators. Ann Intern Med 1999;130:262-269.
70. Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G. Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 2003;95:30-37.
71. Chen WY, Manson JE, Hankinson SE, et al. Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med 2006;166:1027-1032.